Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
Status:
Completed
Trial end date:
2009-05-11
Target enrollment:
Participant gender:
Summary
This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label,
52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia
Purpura (ITP), with a 6-month Safety Follow-up. Patients randomized to romiplostim must
complete the taper or discontinuation of medical SOC for ITP as soon as medically feasible
after the initiation of romiplostim. After the completion or discontinuation of the study
treatment period, any participant who does not transfer in to another romiplostim study will
complete a 6-month Safety Follow-up period.